United Therapeutics (NASDAQ:UTHR) Research Coverage Started at Wells Fargo & Company

Wells Fargo & Company started coverage on shares of United Therapeutics (NASDAQ:UTHR) in a research note published on Monday, Marketbeat.com reports. The brokerage issued an underweight rating and a $414.00 target price on the biotechnology company’s stock.

Several other analysts also recently issued reports on UTHR. JPMorgan Chase & Co. reduced their price target on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a report on Tuesday, July 8th. Royal Bank Of Canada assumed coverage on shares of United Therapeutics in a report on Friday, September 26th. They issued an “outperform” rating and a $569.00 price target on the stock. Jefferies Financial Group upped their price target on shares of United Therapeutics from $432.00 to $564.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. UBS Group upped their price objective on shares of United Therapeutics from $560.00 to $580.00 and gave the company a “buy” rating in a research note on Monday, September 29th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of United Therapeutics in a research note on Wednesday, October 8th. Nine analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $461.62.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $421.64 on Monday. United Therapeutics has a 12-month low of $266.98 and a 12-month high of $459.48. The company has a market capitalization of $19.02 billion, a PE ratio of 16.46, a price-to-earnings-growth ratio of 4.60 and a beta of 0.66. The firm’s 50-day moving average is $393.00 and its two-hundred day moving average is $330.45.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million during the quarter, compared to analysts’ expectations of $802.13 million. During the same period last year, the company earned $5.85 EPS. The firm’s revenue for the quarter was up 11.7% on a year-over-year basis. On average, analysts forecast that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at $11,356,133.75. This trade represents a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total transaction of $9,396,900.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 322,935 shares of company stock worth $133,361,282. 10.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On United Therapeutics

Several large investors have recently made changes to their positions in UTHR. Chung Wu Investment Group LLC bought a new position in United Therapeutics during the 2nd quarter valued at $29,000. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. lifted its position in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares during the last quarter. SVB Wealth LLC bought a new position in shares of United Therapeutics in the 1st quarter worth about $32,000. Finally, Geneos Wealth Management Inc. lifted its position in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.